new thinking on which women should take hormone replacement therapy

August 2001

There's new thinking on which women should take hormone replacement therapy...and for how long.

We used to think that long-term HRT was beneficial for most postmenopausal women because it lowered the risk of heart disease.

Early studies suggested that HRT reduced the risk by 35% to 50%.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

new thinking on which women should take hormone replacement therapy
Cardiology ACE inhibitors and diuretics can prevent recurrent stroke
Cardiology measuring C-reactive protein levels
Infectious Diseases flu vaccine delay again this year
Infectious Diseases Valtrex (valacyclovir) for just 3 days for treating recurrent genital herpes
Pediatrics iron deficiency might reduce cognitive ability in school-aged kids
Osteoporosis best way to switch women from estrogen replacement therapy to Evista (raloxifene)
Osteoporosis Men on gonadotropin-releasing hormone agonists (Lupron, etc) for prostate cancer
Parkinson Disease new treatment algorithm to select drugs for Parkinson's disease
Dermatology topical phenytoin for wound healing
Dermatology Estrostep for acne in young women
Anticoagulants new guidelines on using low-molecular-weight heparins (Lovenox, Fragmin, Innohep)
Thyroid Disorders plans to phase out any levothyroxine products that don't have an approved NDA
Medicare demands for lower cost prescription drugs
Gastroenterology acid blockers for some patients with irritable bowel syndrome
Practice California Board is talking about accepting NABPLEX and licensing pharmacists from other states
Cholesterol Bayer is taking Baycol (cerivastatin) off the market